These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

677 related items for PubMed ID: 10317245

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22. The FDA's generic-drug approval process: similarities to and differences from brand-name drugs.
    Kefalas CH, Ciociola AA.
    Am J Gastroenterol; 2011 Jun; 106(6):1018-21. PubMed ID: 21637264
    [No Abstract] [Full Text] [Related]

  • 23. The debate over substitution policy. Its evolution and scientific basis.
    Schwartz LL.
    Am J Med; 1985 Aug 23; 79(2B):38-44. PubMed ID: 3898831
    [Abstract] [Full Text] [Related]

  • 24. Generic low-molecular-weight heparins: some practical considerations.
    Fareed J, Leong WL, Hoppensteadt DA, Jeske WP, Walenga J, Wahi R, Bick RL.
    Semin Thromb Hemost; 2004 Dec 23; 30(6):703-13. PubMed ID: 15630677
    [Abstract] [Full Text] [Related]

  • 25. New York State and drug lists: a history of confusion.
    Stetler CJ.
    Med Mark Media; 1978 Sep 23; 13(9):36, 38, 40 passim. PubMed ID: 10316687
    [No Abstract] [Full Text] [Related]

  • 26. Current issues in the pioneer versus generic drug wars.
    Safir PO.
    Food Drug Law J; 1995 Sep 23; 50(2):335-9. PubMed ID: 10343002
    [No Abstract] [Full Text] [Related]

  • 27. Brand-name drug manufacturers risk antitrust violations by slowing generic production through patent layering.
    Paine CS.
    Seton Hall Law Rev; 2003 Sep 23; 33(2):479-510. PubMed ID: 12715807
    [No Abstract] [Full Text] [Related]

  • 28. Thalidomide and beyond: some recommendations regarding public policies toward the ethical drug industry.
    Schifrin LG.
    Int J Health Serv; 1974 Sep 23; 4(1):147-55. PubMed ID: 4829893
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Benefits and liabilities of generic prescribing.
    Lee AM.
    W V Med J; 1972 Jun 23; 68(6):161-6. PubMed ID: 4504384
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. Therapeutic equivalents in clinical practice.
    Benson MD.
    Int J Fertil Womens Med; 2001 Jun 23; 46(2):89-94. PubMed ID: 11374660
    [Abstract] [Full Text] [Related]

  • 34. Generic drugs and the prescribing physician.
    Nightingale SL, Morrison JC.
    JAMA; 1987 Sep 04; 258(9):1200-4. PubMed ID: 3626003
    [Abstract] [Full Text] [Related]

  • 35. United States Food and Drug Administration requirements for approval of generic drug products.
    Meyer MC.
    J Clin Psychiatry; 2001 Sep 04; 62 Suppl 5():4-9; discussion 23-4. PubMed ID: 11305846
    [Abstract] [Full Text] [Related]

  • 36. Assuring total drug quality.
    Simmons HE.
    J Am Pharm Assoc; 1973 Feb 04; 13(2):96-8. PubMed ID: 4686621
    [No Abstract] [Full Text] [Related]

  • 37. Information that brand-name companies do not tell us.
    Marcoux AW.
    Drug Intell Clin Pharm; 1987 Mar 04; 21(3):296-7. PubMed ID: 3569035
    [No Abstract] [Full Text] [Related]

  • 38. Meta-analysis for bioequivalence review.
    Chow SC, Liu J.
    J Biopharm Stat; 1997 Mar 04; 7(1):97-111. PubMed ID: 9056591
    [Abstract] [Full Text] [Related]

  • 39. Generic vs. brand name drugs--patients, pharmacists, physicians: caught in the middle.
    Felch WC.
    Internist; 1979 May 04; 20(4):3-5. PubMed ID: 10242131
    [No Abstract] [Full Text] [Related]

  • 40. Regulatory aspects of parenteral drugs.
    Jennings J.
    Bull Parenter Drug Assoc; 1972 May 04; 26(2):53-7. PubMed ID: 5012204
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 34.